ABSTRACT
Background During the first months of the SARS-CoV-2 pandemic, Mexico implemented a national lockdown followed by post-lockdown mitigation.
Methods We used daily number of SARS-CoV-2-confirmed hospitalizations (by date of symptom onset) to assess the changes in the incidence of individuals between the age of 10-59 years during the epidemic in Mexico. For each age group g, we computed the proportion E(g) of individuals in that age group among all cases aged 10-59y during the early lockdown period (April 20–May 3, 2020), and the corresponding proportion L(g) during the late lockdown period (May 18-31, 2020) and post-lockdown mitigation (June 15-28, 2020). For each later period (late lockdown or post-lockdown), we computed the proportion ratios relative to the early lockdown period PR(g)=L(g)/E(g). For each pair of age groups g1,g2, PR(g1)> PR(g2) is interpreted as a relative increase in SARS-CoV-2 infections in the age group g1 compared to g2 for the late lockdown and post-lockdown periods vs. the early lockdown period.
Results For the late lockdown period, the highest PR estimates belong to persons aged 15-19y (PR=1.69(95%CI(1.05, 2.72))) and 20-24y (PR=1.43(1.10,1.86)). For the post-lockdown period, the highest PR estimates were also in age groups 15-19y (PR=2.05(1.30, 3.24)) and 20-24y (PR=1.49(1.15,1.93)). These estimates were higher in persons 15-24y compared to those ≥30y.
Conclusions Our results suggest that adolescents and younger adults had an increased relative incidence during late lockdown and the post-lockdown mitigation periods. The role of these age groups during the epidemic should be considered when implementing future pandemic response efforts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We obtained a waiver for human subjects research review by Instituto Nacional de Salud Publica's IRB. The waiver was signed by Dr. Angelica Angeles Llerenas Chair of the Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos